Human Plasminogen
Biological
Kedrion S.p.A.
Total Payments
$125,750
Transactions
4
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $125,750 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $125,750 | 4 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| COMPASSIONATE USE OF KEDRION HUMAN PLASMINOGEN OPHTHALMOLOGIC DROP PREPARATION IN PATIENTS DIAGNOSED WITH LIGNEOUS CONJUNCTIVITIS: INTERMEDIATE SIZE PATIENT POPULATION EXPANDED ACCESS PROTOCOL | Kedrion S.p.A. | $47,623 | 0 |
| INDIVIDUAL PATIENT IND FOR TREATMENT USE | Kedrion S.p.A. | $47,623 | 0 |
| A Historically-Controlled Phase II/III study to Evaluate Efficacy and Safety of Kedrion Human Plasminogen Eye Drop Preparation in Patients Diagnosed with Ligneous Conjunctivitis | Kedrion S.p.A. | $16,984 | 0 |
| Sponsor Initiated Expanded Access Protocol, Intermediate-Size Patient Population | Kedrion S.p.A. | $13,519 | 0 |
Top Doctors Receiving Payments for Human Plasminogen
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Indianapolis, IN | $125,750 | 4 |
Ad
Manufacturing Companies
- Kedrion S.p.A. $125,750
Product Information
- Type Biological
- Total Payments $125,750
- Total Doctors 0
- Transactions 4
About Human Plasminogen
Human Plasminogen is a biological associated with $125,750 in payments to 0 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is Kedrion S.p.A..
Payment data is available from 2020 to 2020. In 2020, $125,750 was paid across 4 transactions to 0 doctors.
The most common payment nature for Human Plasminogen is "Unspecified" ($125,750, 100.0% of total).
Human Plasminogen is associated with 4 research studies, including "COMPASSIONATE USE OF KEDRION HUMAN PLASMINOGEN OPHTHALMOLOGIC DROP PREPARATION IN PATIENTS DIAGNOSED WITH LIGNEOUS CONJUNCTIVITIS: INTERMEDIATE SIZE PATIENT POPULATION EXPANDED ACCESS PROTOCOL" ($47,623).